Table 1.
Characteristics of patients involved in the study.
| Patients characteristics | N° | % | p (OS) | HR | p (DFS) | HR |
|---|---|---|---|---|---|---|
| Age (y) | ||||||
| Median | 63 | 0.319 | 1.572 | 0.772 | 1.088 | |
| Range | 37–77 | |||||
| Gender | ||||||
| Female, n (%) | 44 | 49 | ||||
| Male, n (%) | 46 | 51 | 0.784 | 0.892 | 0.1 | 0.626 |
| Tumor stage | ||||||
| T1, n (%) | 1 | 1 | ND | ND | ||
| T2, n (%) | 2 | 2 | ||||
| T3, n (%) | 86 | 96 | ||||
| T4, n (%) | 1 | 1 | ||||
| Nodal stage | ||||||
| N0, n (%) | 13 | 14 | ||||
| N+, n (%) | 77 | 86 | 0.441 | 1.768 | 0.408 | 1.435 |
| Metastasis stage | ||||||
| M0, n (%) | 90 | 100 | ||||
| M+, n (%) | 0 | 0 | ND | ND | ||
| Location | ||||||
| Head, n (%) | 71 | 79 | ||||
| Body/tail, n (%) | 19 | 21 | 0.490 | 0.720 | 0.346 | 0.732 |
| Resection margins | ||||||
| R0, n (%) | 41 | 46 | ||||
| R1, n (%) | 49 | 54 | 0.394 | 1.441 | 0.121 | 1.573 |
| Adjuvant therapy | ||||||
| No, n (%) | 16 | 18 | ||||
| Yes, n (%) | 74 | 82 | 0.157 | 0.510 | 0.038 | 0.502 |
| Non-gemcitabine based, n (%) | 2 | 3 | ||||
| Gemcitabine-based, n (%) | 72 | 97 | ND | ND | ||
| Radiotherapy | ||||||
| No, n (%) | 65 | 72 | ||||
| Yes, n (%) | 25 | 28 | 0.383 | 0.643 | 0.430 | 0.775 |
| Tumor grade | ||||||
| G1, n (%) | 7 | 8 | ||||
| G2, n (%) | 58 | 64 | ||||
| G3, n (%) | 25 | 28 | 0.001 | 3.986 | 0.012 | 2.109 |
HR, hazard ratio; R1, resection denotes a microscopically positive margin; T, Tumor; N, node; G, grade.